Potential for Drug Interactions and Polypharmacy From Treatment of COVID-19 in Long-Term Care.

Blaszczyk, Amie Taggart; Sandlin, Katherine; Mirza, Sumeen; Hernandez, Lilibeth; Bader, Hiba; Hall, Ronald G

Blaszczyk, Amie Taggart; Sandlin, Katherine; Mirza, Sumeen; Hernandez, Lilibeth; Bader, Hiba; Hall, Ronald G.

Blaszczyk AT; Division of Geriatrics, Department of Pharmacy Practice, Texas Tech University Health Sciences Center School of Pharmacy, Dallas, TX, USA.
Sandlin K; Texas Tech University Health Sciences Center School of Pharmacy, Dallas, TX, USA.
Mirza S; Texas Tech University Health Sciences Center School of Pharmacy, Dallas, TX, USA.
Hernandez L; Texas Tech University Health Sciences Center School of Pharmacy, Dallas, TX, USA.
Bader H; Texas Tech University Health Sciences Center School of Pharmacy, Dallas, TX, USA.
Hall RG; Division of Clinical and Translational Sciences, Department of Pharmacy Practice, Texas Tech University Health Sciences Center School of Pharmacy, Dallas, TX, USA; Dose Optimization and Outcomes Research (DOOR) Program, Dallas, TX, USA.

J Am Med Dir Assoc ; 23(6): 949-950, 2022 06.

Article in English | MEDLINE | ID: covidwho-1773435

Subject(s)

COVID-19; Polypharmacy; Drug Interactions; Humans; Long-Term Care; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Polypharmacy / COVID-19 Topics: Long Covid Limits: Humans Language: English Journal: J Am Med Dir Assoc Journal subject: History of Medicine / Medicine Year: 2022 Document Type: Article Affiliation country: J.jamda.2022.03.016

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google